Literature DB >> 15743367

Temporal trends in new diagnoses of colorectal cancer with obstruction, perforation, or emergency admission in Ontario: 1993-2001.

Linda Rabeneck1, Lawrence F Paszat, Deanna M Rothwell, Jingsong He.   

Abstract

OBJECTIVES: Previous studies have shown that patients newly diagnosed with colorectal cancer requiring emergency admission to hospital or presenting with obstruction or perforation (defined here as OPE) have advanced disease. None of these studies, however, has evaluated temporal trends in these adverse outcomes, which may reflect screening failures. We evaluated temporal trends in the proportion of Ontario patients with a new diagnosis of colorectal cancer and OPE.
METHODS: Data were obtained from four sources: the Ontario Cancer Registry (OCR); the Canadian Institute for Health Information (CIHI) database, which contains diagnostic information on all patients discharged from hospitals; the Ontario Health Insurance Plan (OHIP) database, which records all physician claims in Ontario; and the Registered Persons Database, which contains demographic information on all Ontario residents covered under OHIP. We calculated the proportion of patients (>/=20 yr) with a new diagnosis of colorectal cancer recorded in CIHI who presented with OPE between 1993 and 2001. These patients were assigned to one of three cohort years: 1993-1995, 1996-1998, or 1999-2001. Those who received chemotherapy, radiotherapy, or palliative care before their first admission to hospital were excluded. We repeated the analysis using the number of OPE patients identified from CIHI in the numerator, and the number of patients (>/=20 yr) with a new diagnosis of colorectal cancer recorded in the OCR in the denominator. Adjusted risk of OPE was calculated using a logistic regression model.
RESULTS: Between 1993 and 2001, 59,670 patients with a new diagnosis of colorectal cancer were recorded in the CIHI database and 54,103 in the OCR. The proportion of these patients with OPE recorded in the CIHI decreased significantly over time: 23.8% (95% CI = 23.2-24.4%) during 1993-1995, 19.4% (95% CI = 18.8-20.0%) during 1996-1998, and 18.1% (95% CI 17.6-18.6%) during 1999-2001 (a 24% relative decrease over time). The relative decrease calculated from OCR data was similar. The adjusted relative decrease in the proportion of patients with OPE during 1993-2001 was 31%.
CONCLUSIONS: Much greater emphasis on screening is needed since approximately 20% of patients with a new diagnosis of colorectal cancer in 1999-2001 presented with OPE.

Entities:  

Mesh:

Year:  2005        PMID: 15743367     DOI: 10.1111/j.1572-0241.2005.41228.x

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  12 in total

1.  Predictors of adjuvant treatment for pancreatic adenocarcinoma at the population level.

Authors:  D J Kagedan; M E Dixon; R S Raju; Q Li; M Elmi; E Shin; N Liu; A El-Sedfy; L Paszat; A Kiss; C C Earle; N Mittmann; N G Coburn
Journal:  Curr Oncol       Date:  2016-10-25       Impact factor: 3.677

2.  Tumor characteristics associated with malignant large bowel obstruction in stage IV colorectal cancer patients undergoing chemotherapy.

Authors:  Duk Hwan Kim; Bun Kim; Jae Hyuk Choi; Soo Jung Park; Sung Pil Hong; Jae Hee Cheon; Won Ho Kim; Tae Il Kim
Journal:  Int J Colorectal Dis       Date:  2016-09-09       Impact factor: 2.571

3.  The association of adjuvant therapy with survival at the population level following pancreatic adenocarcinoma resection.

Authors:  Daniel J Kagedan; Ravish S Raju; Matthew E Dixon; Elizabeth Shin; Qing Li; Ning Liu; Maryam Elmi; Abraham El-Sedfy; Lawrence Paszat; Alexander Kiss; Craig C Earle; Nicole Mittmann; Natalie G Coburn
Journal:  HPB (Oxford)       Date:  2016-02-09       Impact factor: 3.647

4.  Economic impacts of care by high-volume providers for non-curative esophagogastric cancer: a population-based analysis.

Authors:  Julie Hallet; Nicole J Look Hong; Victoria Zuk; Laura E Davis; Vaibhav Gupta; Craig C Earle; Nicole Mittmann; Natalie G Coburn
Journal:  Gastric Cancer       Date:  2019-12-13       Impact factor: 7.370

5.  Variation in receipt of therapy and survival with provider volume for medical oncology in non-curative esophago-gastric cancer: a population-based analysis.

Authors:  Julie Hallet; Laura E Davis; Alyson L Mahar; Ying Liu; Victoria Zuk; Vaibhav Gupta; Craig C Earle; Natalie G Coburn
Journal:  Gastric Cancer       Date:  2019-10-18       Impact factor: 7.370

Review 6.  Diagnosis of cancer as an emergency: a critical review of current evidence.

Authors:  Yin Zhou; Gary A Abel; Willie Hamilton; Kathy Pritchard-Jones; Cary P Gross; Fiona M Walter; Cristina Renzi; Sam Johnson; Sean McPhail; Lucy Elliss-Brookes; Georgios Lyratzopoulos
Journal:  Nat Rev Clin Oncol       Date:  2016-10-11       Impact factor: 66.675

7.  Improving survival in colorectal cancer: what role for general practice?

Authors:  Greg Rubin; David Weller
Journal:  Br J Gen Pract       Date:  2013-04       Impact factor: 5.386

8.  Clinicopathological analysis of factors related to colorectal tumor perforation: influence of angiogenesis.

Authors:  Vicente Medina-Arana; Antonio Martínez-Riera; Luciano Delgado-Plasencia; Diana Rodríguez-González; Alberto Bravo-Gutiérrez; Hugo Álvarez-Argüelles; Antonio Alarcó-Hernández; Eduardo Salido-Ruiz; Antonia M Fernández-Peralta; Juan J González-Aguilera
Journal:  Medicine (Baltimore)       Date:  2015-04       Impact factor: 1.889

9.  Missed opportunities: racial and neighborhood socioeconomic disparities in emergency colorectal cancer diagnosis and surgery.

Authors:  Sandi L Pruitt; Nicholas O Davidson; Samir Gupta; Yan Yan; Mario Schootman
Journal:  BMC Cancer       Date:  2014-12-09       Impact factor: 4.430

10.  Colonic Stents for Colorectal Cancer Are Seldom Used and Mainly for Palliation of Obstruction: A Population-Based Study.

Authors:  Anna M Borowiec; Charlie S K Wang; Elaine Yong; Calvin Law; Natalie Coburn; Rinku Sutradhar; Nancy Baxter; Lawrence Paszat; Jill Tinmouth
Journal:  Can J Gastroenterol Hepatol       Date:  2016-03-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.